ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Inflammatory bowel disease (IBD) affects between 2.4 and 3.1 million people across the United States, according to the ...

Local philanthropists Larry Sears and Sally Zlotnick Sears awarded a “transformative” $1 million gift to the Crohn’s & ...

It basically kept getting passed off as, like, anxiety or stress since I was meeting someone new and eating new foods...” ...

Coffee by itself does not irritate ulcerative colitis ... is a lack of research on caffeine and UC symptoms, the Crohn’s & Colitis Foundation lists coffee and other caffeinated drinks like ...

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...

ustekinumab may offer additional benefits in reducing mortality risks in both ulcerative colitis and Crohn's disease patients and also in lowering VTE risks in ulcerative colitis patients over 3 ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...